Jaime Fergie
Pediatric Infectious Diseases · Corpus Christi, TXNPI 1679533368
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Pfizer at 32.1% of the total. Among pediatric infectious diseases clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 993 payments — averaging $1095.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$349K
- GSK$269K
- Sanofi Pasteur Inc.$225K
- Merck$87K
- Biofire Diagnostics, LLC$34K
- Modernatx, Inc.$31K
- plus $92K from 26 others
Across 132 payments — averaging $21,604 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2.4M
- Merck$247K
- AstraZeneca$115K
- Astrazeneca UK Limited$71K
What the payments were for
- Consulting fees$230,05621%
- Speaking & faculty fees$642,83659%
- Travel & lodging$193,89118%
- Food & beverage$20,7122%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 241 | $348,577 |
| GSK | 318 | $268,960 |
| Sanofi Pasteur Inc. | 206 | $225,399 |
| Merck | 81 | $87,193 |
| Biofire Diagnostics, LLC | 17 | $34,252 |
| Modernatx, Inc. | 17 | $31,027 |
| Sanofi | 6 | $28,411 |
| Sobi, Inc | 43 | $24,681 |
| Biomerieux Inc | 13 | $21,408 |
| AstraZeneca(2 entities) | 5 | $6,369 |
| Novavax Inc | 9 | $5,721 |
| Argenx US, Inc. | 1 | $1,875 |
| Seqirus USA Inc | 1 | $1,158 |
| Mirum Pharmaceuticals, Inc. | 4 | $471 |
| Biogen | 5 | $382 |
| Regeneron Healthcare Solutions, Inc. | 4 | $263 |
| Travere Therapeutics, Inc. | 2 | $240 |
| Pharming Healthcare, Inc. | 2 | $224 |
| Insmed, Inc. | 2 | $127 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Rhythm Pharmaceuticals, Inc. | 1 | $112 |
| Phadia US Inc. | 2 | $104 |
| Ultragenyx Pharmaceutical Inc. | 1 | $100 |
| Novartis | 1 | $90 |
| Genentech, Inc. | 1 | $73 |
| Mylan Specialty L.p. | 2 | $33 |
| Philips North America LLC | 2 | $31 |
| Genentech USA, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Vivus LLC | 1 | $19 |
| Chiesi USA, Inc. | 1 | $14 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEXSERO$222,118
- ABRYSVO$84,236
- BEYFORTUS$76,640
- TRUMENBA$72,094
- PREVNAR 20$68,323
- PENBRAYA$62,060
- FLUZONE HIGH-DOSE$26,445
- Synagis$24,068
- Film Array System$23,936
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$17,484
- PREVNAR - 13$12,541
- ENFLONSIA$12,029
- Moderna Covid-19 Vaccine$11,600
- BIOFIRE SPOTFIRE Respiratory (R) Panel$11,502
- FLUZONE QUADRIVALENT$9,318
- FLUBLOK QUADRIVALENT$7,443
- BioFire FilmArray$5,875
- NOVAVAX COVID-19 VACCINE, ADJUVANTED$5,564
- BIOFIRE SPOTFIRE Control Station$5,175
- MENQUADFI$4,005
How this compares
$1,087,495 in reported general payments places this provider in the 95th percentile of 66 pediatric infectious diseases providers in Texas.
Other pediatric infectious diseases in Corpus Christi
- Flor de Maria MunozHouston$268K
- Lawrence StanberryGalveston$225K
- Janak PatelGalveston$118K
- Rene AmayaHouston$43K
- Denver NilesHouston$41K
- Micah BhattiHouston$31K
- Carol BakerHouston$30K
- Gloria HeresiHouston$22K
- Dennis ConradSan Antonio$17K
- Coburn AllenAustin$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.